Consequently, our findings suggest that targeting PDK may constitute a promising strategy for augmenting the efficacy of ICB therapy with PD-L1 antibodies, offering potential benefits for patients with advanced gastric cancer. This evidence concerns the gene CD274 and gastric cancer.